Canlyniadau Chwilio - Jean‐Pierre Armand

  • Dangos 1 - 10 canlyniadau o 10
Mireinio'r Canlyniadau
  1. 1
    Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

    Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy gan Eric Raymond, Sandrine Faivre, Jean Pierre Armand

    Cyhoeddwyd 2000
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    An Electrophysiological Study of the Postnatal Development of the Corticospinal System in the Macaque Monkey

    An Electrophysiological Study of the Postnatal Development of the Corticospinal System in the Macaque Monkey gan Etienne Olivier, S. A. Edgley, Jean Pierre Armand, Roger Lemon

    Cyhoeddwyd 1997
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity

    Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity gan Ali N. Chamseddine, Michel Ducreux, Jean‐Pierre Armand, Xavier Paolettí, Tuvana Satar, Angélo Paci, Olivier Mir

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin

    Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin gan Hussein Sadek, N. Azli, J. L. Wendling, Esteban Cvitkovic, Mohamed Rahal, G. Mamelle, J. C. Guillaume, Jean Pierre Armand, Marie France Avril

    Cyhoeddwyd 1990
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

    Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer gan Éric Raymond, Jérôme Alexandre, Sandrine Faivre, Karina Vera, Eric Materman, Joseph Boni, Cathie Leister, Joan Korth‐Bradley, Axel R. Hanauske, Jean‐Pierre Armand

    Cyhoeddwyd 2004
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

    Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials gan G G Chabot, D Abigerges, G. Catimel, Stéphane Culine, M Forni, Jean Marc Extra, M. Mahjoubi, Patrice Herait, Jean‐Pierre Armand, R. Bugat

    Cyhoeddwyd 1995
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

    Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma gan Éric Raymond, Michel Fabbro, Valérie Boige, Olivier Rixe, Marc Frénay, Gilles Vassal, Sandrine Faivre, Evelyne Sicard, Caroline Germa, J.M. Rodier, Laurent Vernillet, Jean‐Pierre Armand

    Cyhoeddwyd 2003
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

    Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies gan Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, Nora Ady-vago, Cecilia Guzmán, Luis López Lázaro, Stéphanie Lozahic, José Jimeno, Fernando Pico, Jean Pierre Armand, José A. López-Martín, Éric Raymond

    Cyhoeddwyd 2005
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

    Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer gan Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo L. Bello, Samuel E. DePrimo, Nicoletta Brega, Giorgio Massimini, Jean‐Pierre Armand, P. Scigalla, Éric Raymond

    Cyhoeddwyd 2005
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib

    A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib gan Thibault De La Motte Rouge, Lorenzo Galluzzi, Ken A. Olaussen, Yaël Zermati, Ezgi Tasdemir, Thomas Robert, Hugues Ripoche, Vladimir Lazar, Philippe Dessen, Francis Harper, Gérard Pierron, Guillaume Pinna, Natália de Souza Araujo, Annick Harel-Belan, Jean‐Pierre Armand, Tai W. Wong, Jean Charles Soria, Guido Kroemer

    Cyhoeddwyd 2007
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: